Conditions: Coronary Artery Disease
Keywords: CAD prasugrel ticagrelor antiplatelet thienopyridine P2Y12 Inhibitors
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 110
Healthy volunteers: no

Brief summary:
This is a Phase 4, multicenter, open-label (blinded Pharmacodynamic PD results), randomized, 3-arm, parallel-design study of subjects with stable Coronary Artery Disease CAD. This study will compare the PD effect of prasugrel 10 mg QD (once-daily) maintenance dose with ticagrelor 90 mg BID (twice daily) maintenance dose in subjects with stable CAD who have previously received ticagrelor loading does (LD) and maintenance dose (MD)..

Detailed description:

Arms:
arm 1: Prasugrel 10 mg QD MD arm 2: Ticagrelor 90 mg twice-daily (BID) MD arm 3: Prasugrel 60mg Loading Dose (LD), followed by prasugrel 10mg once-daily (QD) Maintenance Dose (MD)

Interventions: intervention 1: Prasugrel Loading Dose intervention 2: Prasugrel Maintenance Dose intervention 3: Ticagrelor Maintenance Dose
Intervention descriptions: intervention 1: 60mg given as six 10mg film coated tablets intervention 2: 10mg maintenance dose, given as one 10mg film coated tablet intervention 3: one 90mg film coated tablet

Protocol document: